Sanofi - pharmaceutical segment revenues by product group 2017-2019
This statistic shows the revenue of Sanofi's pharmaceutical segment by product groups from 2017 to 2019. In 2019, Sanofi's pharmaceutical group generated 1.7 billion euros in revenue oncology products. Sanofi is one of the top global pharmaceutical companies. It is headquartered in Paris, France.
Sanofi's segments
Sanofi’s pharmaceutical segment generated 5.1 billion euros in revenue through its diabetes product group in 2019, a decrease compared to nearly 5.5 billion euros in 2018. Lantus is one of Sanofi’s best selling pharmaceutical products. Its revenue has risen from 2.4 billion euros in 2008 to 6.39 billion euros in 2015, but decreased to three billion in 2019. Lantus is an insulin glargine used daily to control blood sugar levels of patients with diabetes. Clopidogrel, which is marketed under Sanofi’s trade name Plavix, generated 1.33 billion euros in 2019. Plavix is an oral agent that prevents blood clots in patients with some types of heart disease and also prevents heart attacks.
Among its vaccination segment, Sanofi has several profitable products. The company’s influenza vaccines generated some 1.9 billion euros in 2019. Fluzone is a marketed brand of Sanofi’s influenza vaccine, of which varieties exist to target persons of certain age groups.
Sanofi originated in 1973 as a subsidiary of Elf Aquitaine, the company ventured into the U.S. market in 1994. Although, the company is primarily focused on the pharmaceutical market, it also maintains an animal health segment. This segment develops products in four groups including antiparasitics and antiinfectives. Sanofi generated some 36 billion euros in total revenues in 2019. The company expended approximately six billion euros the same year on research and development ventures.
Sanofi's segments
Sanofi’s pharmaceutical segment generated 5.1 billion euros in revenue through its diabetes product group in 2019, a decrease compared to nearly 5.5 billion euros in 2018. Lantus is one of Sanofi’s best selling pharmaceutical products. Its revenue has risen from 2.4 billion euros in 2008 to 6.39 billion euros in 2015, but decreased to three billion in 2019. Lantus is an insulin glargine used daily to control blood sugar levels of patients with diabetes. Clopidogrel, which is marketed under Sanofi’s trade name Plavix, generated 1.33 billion euros in 2019. Plavix is an oral agent that prevents blood clots in patients with some types of heart disease and also prevents heart attacks.
Among its vaccination segment, Sanofi has several profitable products. The company’s influenza vaccines generated some 1.9 billion euros in 2019. Fluzone is a marketed brand of Sanofi’s influenza vaccine, of which varieties exist to target persons of certain age groups.
Sanofi originated in 1973 as a subsidiary of Elf Aquitaine, the company ventured into the U.S. market in 1994. Although, the company is primarily focused on the pharmaceutical market, it also maintains an animal health segment. This segment develops products in four groups including antiparasitics and antiinfectives. Sanofi generated some 36 billion euros in total revenues in 2019. The company expended approximately six billion euros the same year on research and development ventures.
